Weighing the benefits and risks of hormone therapy for transgender patients.
BOSTON — In the treatment of transgender men and women, clinicians should carefully weigh the known benefits of hormone therapy against the potential risks, according to Madeline B. Deutsch, MD, of the University of California, San Francisco Medical Center.
During a symposium on the current state of transgender medicine at ENDO 2016, Dr Deutsch discussed the options for hormone therapy and mainstays of management for transgender men and women. In this video, she elaborates on data that alleviate concerns about risks associated with certain treatments, such as an increased risk for thromboembolic disease with estrogen therapy, and how clinicians should approach management of this patient population.
Enjoying our content?
Thanks for visiting Endocrinology Advisor. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Endocrinology Advisor. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.